Dermatologic
15 cases on atopic dermatitis management (JAK inhibitor selection with cardiovascular risk, reactive versus scheduled maintenance steroid therapy, infant facial eczema, refractory pediatric disease, dupilumab dual-indication and add-on biologic decisions), allergic contact dermatitis, chronic spontaneous urticaria (antihistamine updosing, omalizumab escalation, autoimmune-marker-guided therapy), cold urticaria and anaphylaxis risk, hereditary and ACE-inhibitor angioedema, and idiopathic angioedema without hives — choose a case below to open its full multi-voice debate.
A pastry chef with refractory atopic dermatitis and a prior unprovoked DVT forces a real choice between JAK-inhibitor speed and biologic safety margin.
A mother's fear of repeated steroid courses collides with the case for scheduled twice-weekly maintenance therapy in a child's relapsing eczema.
A 14-month-old's facial eczema puts a topical calcineurin inhibitor's boxed warning against a steroid's real atrophy risk on thin facial skin.
A 5-year-old's refractory eczema is missing him soccer and sleep, and the real choice is an intensive week of wet-wrap therapy against the wait for biologic approval.
A hairdresser's severe facial and hand dermatitis pits an immediate steroid taper against patch testing that only works if steroids are held first.
An avid hiker's chronic hives raise the guideline-sanctioned step of fourfold antihistamine updosing against moving straight to omalizumab.
Six months of standard-dose omalizumab hasn't cleared her hives, and the choice between dose escalation, cyclosporine, and a newly approved oral BTK inhibitor is genuinely unsettled.
A positive autologous serum skin test in a nurse's chronic hives raises a real question: does the autoimmune label change the treatment ladder or just describe it.
An open-water swimmer's cold urticaria raises deliberate cold-tolerance induction against strict avoidance, with the induction protocol's own safety risk complicating the choice.
An attorney's twice-monthly hereditary angioedema attacks test the guideline threshold for starting long-term prophylaxis against the real cost and burden of committing to it.
A man's tongue and lip swelling on lisinopril raises bradykinin-targeted therapy against a genuinely mixed trial record, with real airway signs forcing a decision before the evidence resolves.
A mother of teenagers has recurring angioedema with normal complement and no hives, and the safer diagnostic-therapeutic trial isn't the one that matches her actual symptom pattern.
Dupilumab covers both a warehouse worker's eczema and asthma cleanly, but a marathon runner already stable on mepolizumab makes the same one-drug logic genuinely uncertain.
A gardener's skin has cleared beautifully on dupilumab, but the itch that's still keeping her up at night raises a genuinely separate mechanism, not just an underdosed one.
A nursing student starting long-term HAE prophylaxis has trial evidence pointing one way and her insurance formulary pointing another, with a future pregnancy ruling out the oldest option outright.